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Introduction
Despite advances that have been made in the management of myeloid leukemia, the prognosis of patients with acute myeloid leukemia (AML) and blast-phase or tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) remains dismal (1, 2) .
This highlights the need for the identification of novel therapeutic strategies for the management of this group of aggressive diseases. Chemotherapy and TKIs remain the cornerstone therapies for the treatment of patients with AML and CML, respectively, while allogeneic stem cell transplantation (allo-SCT) is the main immunotherapeutic modality for patients with aggressive forms of AML and blast-phase or TKI-resistant CML. However, because of its significant toxicity, allo-SCT is reserved for patients with aggressive or relapsed disease. In addition to allo-SCT, immunotherapy in the form of vaccines and antibodies has demonstrated efficacy in the management of patients with AML and CML, but for the most part remains investigational.
In order to minimize the toxicity of allo-SCT while taking advantage of the graft versus leukemia (GvL) effect, numerous leukemia-associated antigens (LAAs) including PR1 (3), WT1 (4) and RHAMM (5) , and leukemia-specific antigens such as BCR-ABL (6) have been identified and shown to elicit leukemia-specific immune responses.
However, because of the heterogeneity of myeloid leukemia (7-9) and since cancerous cells can alter antigen expression to evade the immune system (10) (11) (12) , it appears that targeting a single antigen is insufficient to completely eradicate malignantly transformed cells. Studies have been conducted targeting multiple epitopes from a single antigen evidenced by the success of allo-SCT, emphasize the need to identify novel antigens that can be targeted individually or as a part of combination immunotherapeutic approaches.
Cathepsin G (CG) is a serine protease restricted to cells of myeloid lineage and is expressed within myeloid azurophil granules along with neutrophil elastase (NE) and proteinase-3 (P3); the latter two proteases are the source proteins for the PR1 epitope. CG is involved in host immunity, cleavage of inflammatory mediators and receptors, and degradation of extracellular matrix components (18, 19) . Like NE and P3, high level of CG transcription is seen at the promyelocytic stage of granulocyte development (20) .
Furthermore, CG is overexpressed in myeloid leukemia blasts (21) , and was shown to be Since we previously showed that NE and P3 are aberrantly expressed by myeloid leukemia blasts (23) , and because CG is also a component of azurophil granules, we investigated whether CG is aberrantly expressed in AML, which could make it an ideal target for leukemia immunotherapy. In this report, we identify CG1 (FLLPTGAEA), a naturally processed HLA-A*0201 restricted peptide derived from CG, in AML and demonstrate its high affinity to HLA-A*0201. We show that CG is aberrantly expressed in AML blasts and stem cells, and that CG1-CTLs specifically kill CG-expressing leukemia targets. Finally, we show functional CG1-CTLs in patients with AML fetal bovine serum (FBS) (Gemini Bio-Products), Penicillin (100 U/mL)/ Streptomycin (100 μg/mL) (Cellgro) and were kept in 5% CO 2 at 37 °C. 
Western blotting and immunoprecipitation (IP)
Whole cell lysates (WCL) from AML samples were generated using standard methodology with RIPA buffer (50 mM TrisHCl (pH 8); 150 mM NaCl; 1% NP-40; 0.1% SDS; 0.5% sodium deoxycholate). Purified CG (Sigma) and P3 (Athens Research and Technology) were used as positive controls; U-937 WCL was used as NE positive Chemiluminescence was captured on Kodak film and digitally using Molecular Imager ChemiDoc XRS+ (BIO-RAD).
CG peptide binding
Immune epitope database (IEDB) binding algorithms were used to identify CG peptides with highest binding affinities (www.immuneepitope.org) (24) . Peptide binding was subsequently confirmed using standard peptide-T2 binding assays (25, 26) . Briefly, T2 cells were washed and then incubated at 37 °C in serum-free media containing increasing concentrations of CG-peptides (BioSynthesis) (Supplementary Table S1) Results were graphed relative to the positive control peptide as 100% binding at each time point. The t 1/2 was calculated using GraphPad Prism's nonlinear regression, 'dissociation -one phase exponential decay' curve (27) .
Fluorescent confocal microscopy and flow cytometry analysis
To determine intracellular CG expression, cells were washed, fixed with 4% paraformaldehyde, permeabilized and stained with Alexa-647 directly conjugated anti-CG antibody (Santa Cruz); we used the Alexa-647 conjugation kit (Invitrogen) to conjugate anti-CG to fluorophore. Aqua live/dead stain (Invitrogen) was used to assess viability in flow cytometry experiments. For confocal imaging, after staining, cells were 
Peptide-specific CTL lines
Peptide-specific CTLs were expanded by stimulating PBMCs from healthy HLA-A*0201 individuals with peptide in vitro, as previously described (3, 30 cells were washed in serum-free RPMI 1640 medium and incubated with CG1 or negative control peptide PR1 at 20 µg/mL for 90 minutes at 37°C. Peptide-loaded T2 cells were irradiated with 7500 cGy, washed, and cultured with freshly isolated PBMCs at a 1:1 ratio in RPMI 1640 medium supplemented with 10% human AB serum. Cultures were re-stimulated with peptide-pulsed T2 cells on days 7, 14, and 21, and the following day 20 IU/mL of recombinant human interleukin-2 (rhIL-2; Invitrogen) was added.
Cell-mediated cytotoxicity assay
A standard calcein AM cytotoxicity assay was used to determine specific lysis as described previously (31, 32) . Briefly, 1000 target cells in 10 µl (1.0 x10 Unpulsed T2 cells were used as negative stimulator controls. Fluorescence minus one (FMO) controls were performed for each sample and background staining was subtracted from each experimental group.
Statistical Analysis
GraphPad Prism 5.0 software was used to perform statistical analyses and P-values <0.05 were used to establish significance.
Research. 
Results

CG is aberrantly expressed in primary AML and is ubiquitinated
We first examined the expression of CG by AML from patient samples with high peripheral blood blasts that were obtained at the time of original diagnosis. We initially examined 12 patient samples for CG expression and we present the immunoblots from 8 AML patient samples representing various AML subtypes. We performed western immunoblots on primary patient AML blasts, which demonstrated CG expression in a number of AML subtypes ( Fig. 1A ; Supplementary Table S2) . We also examined these samples for expression of NE and P3, the two azurophil granule proteases from which the PR1-peptide is derived and that share a common promoter (3, 31, 32) . Our data show lower expression of NE and P3 in the samples we used in our studies, compared with CG.
Furthermore, there was no correlation between CG expression and NE or P3 expression.
Because CG is located on a different chromosome (chromosome 14) than NE and P3 (33, 34) , which are both located on chromosome 19 (35, 36) , and since CG is expressed later than NE and P3 during the maturation of the myeloid progenitor under the regulation of a different promoter than NE and P3 (20, 37) , it is not surprising that levels of NE and P3 did not correlate with CG expression. Furthermore, we demonstrate higher expression of CG in primary AML than in normal granulocytes (Fig. 1B) .
Because protein ubiquitination facilitates proteasomal degradation of antigens for processing on MHC class I (38, 39), we investigated whether CG was also ubiquitinated in AML, thereby facilitating CG-derived peptide presentation on the leukemia cell ( Supplementary Fig. S1 ). Furthermore, because cytosolic proteins are favored for antigen processing since they have direct access to the proteasome (40), we studied the subcellular localization of CG in AML and normal neutrophils. Our data show that CG is diffusely localized in AML in contrast with normal granulocytes, where it is located primarily in granules, as evidenced by distinct foci of staining in the normal granulocyte samples ( Fig. 2A) . We confirmed this observation using a high throughput bio-imaging system (BD Pathway 435 cell imager) that demonstrated the distribution of CG outside granules in a large number of leukemia blasts (AML #2 n=892 cells; AML #5 n=484 cells) ( Fig. 2B and C) . We show that 95% of normal granulocytes have a granular pattern demonstrated by a dim:bright ratio<0.6, in contrast to 1% and 9% of the blasts in AML #2 and AML #5 samples, respectively. Together, these data show aberrant diffuse localization of CG outside granules and ubiquitination in AML, suggesting preferential processing of CG in AML for presentation on MHC class I.
Multiple HLA-A*0201 binding epitopes are derived from CG Five CG derived nonameric peptides were identified using IEDB and SYFPEITHI binding algorithms (Supplementary Table S1 and Fig. 3A ). Although we identified five CG-derived peptides with high binding affinities to HLA-A*0201, we focused our experiments on CG1 peptide because of a prior report showing that CG1 is a naturally processed peptide in chronic myeloid leukemia (21) , and because of our work confirming CG1 on the surface of leukemia cells (Supplementary Fig. S2 ). Using T2 binding and iTopia assays, the CG1 peptide peptides and with the control peptide FLPSDFFPSV (Fig. 3A and 3B) . Furthermore, using iTopia assays we measured the off-rate for CG1 and calculated the time for halfmaximal dissociation of CG1 from HLA-A*0201 (t 1/2 ) to be approximately 14 hours.
CG1-CTL lyse CG-expressing HLA-A*0201 AML
To determine the ability of CG1-CTL to lyse primary AML blasts, we performed calcein AM cytotoxicity assays (31, 32) . We first show dose-dependent specific killing of AML blasts by CG1-CTL, with minimal killing of HLA-A*0201 normal bone marrow ( (Fig. 4B ).
Since we demonstrated HLA-A*0201 restricted specific cytotoxicity of AML blasts by CG1-CTL, we next examined CG1-CTL cytotoxicity using five HLA-A*0201 (Pt. 1-5) and one HLA-A*0201 negative AML patient samples (Pt. 6) (Fig. 4C) 
negative sample. Furthermore, at some of E:T ratios we observed higher specific lysis in some of the AML samples that had higher CG expression. However, there was some variability seen in killing of the AML samples independent of CG expression, suggesting that there may be differences in antigen presentation by the AML target cells that could account for differences in CG1/HLA-A*0201 presentation (Fig. 4C and Supplementary   Fig. S3 ). Moreover, although we were unable to assess MFI of CG expression of Pt. (Fig. 5B) . Since we had to combine NSC from 4 different healthy donors, there may be variability in the expression of CG in NSC from different individuals, which may not be reflected in the mean values presented (Fig. 5B) 
the median and range pixel intensity values of LSC 1 (median=620; range= 82-2474), LSC 2 (median=62; range= 46-2550) and NSC (median= 48; range= 45-497) together suggest higher expression of CG in LSC in comparison with NSC. Furthermore, a significant difference was also observed between the two LSC samples, which can be attributed to leukemia heterogeneity.
Functional CG1-CTL are detected in AML patients following allo-SCT
Since we showed CG expression in AML and lysis of CG-expressing AML by CG1-CTL in vitro, we next investigated whether immunity to CG1 can be detected in AML patients following allo-SCT. CG1/HLA-A*0201 dextramer was used to stain PBMC samples from patients with AML. We show the presence of CG1-CTL in AML patient peripheral blood following allo-SCT (Range, 0.07%-0.44%) at similar frequencies to what was previously detected for PR1-and WT1-CTL (Table 1) (3, 16) . The gating strategy used and the specificity of CG1/HLA-A*0201 dextramer for CG1-CTL is demonstrated in Supplementary Fig. S4 . Furthermore, we demonstrate functionality of patient CG1-CTL using a CFC assay measuring IFN-γ and TNF-α response following CG1-CTL stimulation with CG1-pulsed T2 cells. Although responses were detected in four of the five AML patient samples that were analyzed indicating functional CG1-CTL, they were highly variable ranging from 0.6% to 11%. The absence of a response in one of the samples (Patient 2) could be attributed to the lack of full immune reconstitution seen early following allo-SCT (day 30), since the other patient samples analyzed were collected at later time points following allo-SCT (Range, 205-1162 days).
Discussion
We report the discovery of a novel immunogenic epitope derived from the myeloid azurophil granule protease CG. We show high expression and ubiquitination of CG in AML blasts as well as aberrant CG localization outside azurophil granules, which could facilitate CG antigen presentation by leukemia. Additionally, CG is highly expressed in LSC but not normal hematopoietic stem cells. We identify five CG-derived nonameric peptides that bind with high affinity to HLA-A*0201 and show that the CG1 peptide and CG (46) . In our study, we further characterize the anti-CG immune response in AML and show that CG1 is a naturally processed CG-derived epitope that is likely responsible for the immunity against CG. This epitope, along with CG2 and CG3 (Supplementary Table S1 and Fig. 3 ) are all derived from the signal peptide of CG. Because cleavage of the signal peptide occurs in the endoplasmic reticulum and golgi (47, 48) , two compartments that are involved in MHC class I antigen processing, the presence of the cleaved signal peptide in these compartments may facilitate processing for presentation on MHC class I. Furthermore, although ubiquitination is an important step in antigen degradation during the process of antigen presentation (38, 39) , it may not be significant in the processing of CG1-CG3 peptides since these are naturally found within the signal domain of CG, which is normally cleaved during CG intracellular processing. Whether other CG-derived epitopes (i.e. CG2-CG5) are also immunogenic is the subject of ongoing research in our lab.
Furthermore, we studied whether there was a correlation between the expression of CG and the primary granule serine proteases NE and P3. This was investigated to determine whether targeting CG will add to the existing immunotherapeutic approaches that target PR1 peptide, which is a nonameric peptide derived from NE and P3 that has demonstrated clinical efficacy in vaccine trials of patients with AML, CML and MDS (16). The lack of a correlation between CG expression and NE or P3, as shown in Fig. 1 , adds to the significance of CG as an immunotherapeutic target in AML. Unlike NE and P3, CG is located on chromosome 14 and has a promoter region that differs from NE and P3 (49, 50) . Because of the distinct expression and regulation of CG that is independent of NE and P3 expression, CG may prove to be an effective target in AML that may be resistant to PR1 therapy because of low NE and P3 expression. Additionally, because of the heterogeneity among the leukemia subclones within an individual patient (9), which could account for variable expression of LAA by the leukemia cells, targeting CG could be used in combination with other LAA in a multipeptide immunotherapeutic approach to Gating strategy for CG1/HLA-A*0201 dextramer is shown in Supplementary Fig. S4 . Fig. S3 ). Pt. 6 is HLA-A2 negative. ND indicates not determined by flow cytometry. 
